StoryFunding
Rejuvenate Bio raises $6M led by VCapital and signs an animal-health gene therapy R&D collaboration with Merck Animal Health
Rejuvenate Bio closed a $6M funding round led by VCapital with Merck Animal Health, Kendall Capital Partners, Connecticut Innovations and Digitalis, and launched an R&D collaboration with Merck Animal Health on animal-health gene therapy.
- $6M financing validates platform strength and growing interest in gene therapy for chronic and age-related diseases in companion animals.
- Merck Animal Health collaboration leverages Rejuvenate Bio's platform and translational expertise for veterinary medicine.
- Additional investors include Kendall Capital Partners, Connecticut Innovations and Digitalis; Merck Animal Health also participated.